Abstract: The present invention relates to a stable pharmaceutical composition for injection containing docetaxel and a method of preparing the same. More particularly, the present invention relates to a pharmaceutical composition for injection containing docetaxel having better storage stability than conventional medications, which is prepared by dissolving docetaxel, a water-insoluble compound, in distilled water after mixing it with cyclodextrin (CD) and a water-soluble polymer such as hydroxypropyl methylcellulose (HPMC), polyethylene glycol (PEG) or polyvinylpyrrolidone (PVP) and lyophilizing the mixture, and a method of preparing the same.

Abstract: A user authentication process when a portable terminal receives multimedia broadcasting requiring authentication is provided. The broadcasting is provided by a mobile communication system including a portable terminal capable of a user authentication process if a message indicating that broadcasting requires the authentication process is received while using the broadcast service, the portable terminal provides the broadcast service if the authentication process is successful, and stops the broadcast service if the authentication process fails; and a multimedia broadcast server for transmitting to the portable terminal the message, which indicates that the broadcasting requires the authentication process, when the broadcasting requires the authentication process while the broadcast service is being provided to the portable terminal.

Abstract: There is provided a driving circuit of a light emitting device. The driving circuit of a light emitting may include: a DC/DC converter converting an input DC voltage into an output DC voltage; a light emitting device block including a plurality of LED groups connected to an output terminal of the DC/DC converter; a current source circuit unit including a plurality of current sources; a voltage detection unit detecting the output DC voltage of the DC/DC converter; a minimum voltage detection unit detecting a minimum voltage among a plurality of voltages between the plurality of LED groups and the plurality of current sources, respectively; and a single comparator including a first non-inverting input terminal receiving the voltage detected by the voltage detection unit, a second non-inverting input terminal receiving the minimum voltage detected by the minimum voltage detection unit, and an inverting input terminal receiving a predetermined reference voltage.

Abstract: The present invention relates to a novel benzopyran derivative having goodantagonistic activity on TGF-? receptor which can be effectively used as a prophylactic and therapeutic agent for liver disease as well as several fibroplasiadiseases such as hepatic fibrosis, liver cirrhosis, pulmonary fibrosis, dermatosclerosis, glomerular fibrosis and the like; and a pharmaceutical use thereof.

Abstract: The present invention relates to a method for optical resolution of amlodipines by using isopropanol solvent and optically active O,O?-dibenzoyl tartaric acid as chiral reagent. More particularly, the present invention relates to a method comprising (a) obtaining (R)- or (S)-amlodipine dibenzoyl tartrate salt or solvate thereof by reacting (R,S)-amlodipines with optically active O,O?-dibenzoyl tartaric acid in isopropanol solvent, and (b) treating the (R)- or (S)-amlodipine salt with a base, thus obtaining optically active amlodipine.

Abstract: The present invention relates to a sibutramine-containing inclusion complex having superior storage stability, and particularly to a pharmaceutically stable inclusion complex suitable for the drug formulation, which prepared by reacting a sibutramine (N,N-dimethyl-1-[1-(4-chlorophenyl)-cyclobutyl]-3-methylbutylamine) of Formula 1 and beta-cyclodextrin in a predetermined ratio, its preparation method and a pharmaceutical composition comprising the same.

Abstract: The present invention relates to a process for the preparation of S-(+)-clopidogrel by an optical resolution and, more particularly, to a process for the preparation of S-(+)-clopidogrel represented by the following formula 1 with high optical purity by converting a clopidogrel racemic carboxylic acid into a diastereomeric salt using a (+)-cinchonine for optical resolution, extracting an S-(+)-clopidogrel carboxylic acid from the diastereomeric salt using a suitable solvent under an acidic condition and then reacting the S-(+)-clopidogrel carboxylic acid with methanol.

Abstract: The present invention relates to salts of a pyrrolopyrimidinone derivative having superior PDE-5 inhibition activity and a process for preparing the same. More particularly, the present invention relates to a crystalline acid addition salt prepared by reacting a pyrrolopyrimidinone derivative with an acid selected from gentisic acid, maleic acid, citric acid, fumaric acid and tartaric acid. With no hygroscopic property and superior long-term storage stability, photostability and thermal stability, the salts of the pyrrolopyrimidinone derivative are appropriate to be prepared into medications and, with superior PDE-5 inhibition activity, are useful for the treatment and prevention of erectile dysfunction, pulmonary arterial hypertension, chronic obstructive pulmonary disease, benign prostatic hypertrophy and lower urinary tract diseases.

Abstract: There is provided a driving circuit of a light emitting device. The driving circuit of a light emitting may include: a DC/DC converter converting an input DC voltage into an output DC voltage; a light emitting device block including a plurality of LED groups connected to an output terminal of the DC/DC converter; a current source circuit unit including a plurality of current sources; a voltage detection unit detecting the output DC voltage of the DC/DC converter; a minimum voltage detection unit detecting a minimum voltage among a plurality of voltages between the plurality of LED groups and the plurality of current sources, respectively; and a single comparator including a first non-inverting input terminal receiving the voltage detected by the voltage detection unit, a second non-inverting input terminal receiving the minimum voltage detected by the minimum voltage detection unit, and an inverting input terminal receiving a predetermined reference voltage.

Abstract: Disclosed are an energy recovery apparatus and method for a plasma display panel. The energy recovery apparatus includes a sustain voltage source for supplying a sustain voltage, a panel capacitor formed equivalently at a discharge cell, a first charging circuit for forming a first charging path when one side of the panel capacitor is charged, a second charging circuit for forming a second charging path when the other side of the panel capacitor is charged, a first power circuit for supplying the sustain voltage to the panel capacitor and forming the first charging path, and a second power circuit for supplying a ground voltage generated from a ground voltage source to the panel capacitor and forming the second charging path. The energy recovery apparatus and method according to the present invention can decrease components in number and reduce power consumption and manufacturing cost by charging the other side of the panel capacitor using a charging voltage of one side of the panel capacitor.

Abstract: The invention relates to novel pyridine derivatives having an inhibitory effect on production of cytokines, which are involved in inflammatory responses, thus suggesting its usefulness as therapeutic agents for treating diseases related to inflammation, immune, chronic inflammation as well as an agent having an anti-inflammatory and analgesic effect. Further, this invention relates to a method of manufacturing the same and a pharmaceutical composition containing the same.

Abstract: The present invention relates to a stable pharmaceutical composition for injection containing docetaxel and a method of preparing the same. More particularly, the present invention relates to a pharmaceutical composition for injection containing docetaxel having better storage stability than conventional medications, which is prepared by dissolving docetaxel, a water-insoluble compound, in distilled water after mixing it with cyclodextrin (CD) and a water-soluble polymer such as hydroxypropyl methylcellulose (HPMC), polyethylene glycol (PEG) or polyvinylpyrrolidone (PVP) and lyophilizing the mixture, and a method of preparing the same.

Abstract: The present invention relates to a novel benzopyran derivative having goodantagonistic activity on TGF-? receptor which can be effectively used as a prophylactic and therapeutic agent for liver disease as well as several fibroplasiadiseases such as hepatic fibrosis, liver cirrhosis, pulmonary fibrosis, dermatosclerosis, glomerular fibrosis and the like; and a pharmaceutical use thereof.

Abstract: Disclosed is a method and device for searching for a telephone number in a mobile terminal having a direction key that consists of a left arrow, a right arrow, an up arrow and a down arrow. The method includes displaying one or more consecutive digits input by a user in a standby mode of the mobile terminal; and when a quick search key and any arrow of the direction key are pressed simultaneously, searching for a telephone number including the displayed digits in a position corresponding to the pressed arrow.

Abstract: Disclosed are agents that inhibit histone deacetylase. More specifically, the present invention relates to novel hydroxamic acid derivatives or pharmaceutically acceptable salts thereof for anticancer agents or other therapeutic agents based on their histone deacetylase inhibitory activity.

Abstract: The present invention relates to a process for the preparation of optically pure amlodipine gentisate, more particularly to a continuous process for the preparation of optically pure amlodipine gentisate with good yield and high optical purity. The processes can be preformed by first reacting racemic (R,S)-amlodipine and optically pure O,O?-dibenzoyltartaric acid in the presence of a solvent including isopropanol to prepare (R)- or (S)-amlodipine dibenzoyltartarate diastereomer or a solvate thereof, treating the prepared amlodipine diastereomeric salt or a solvate thereof with a base and then finally adding gentisic acid.

Abstract: The present invention relates to an acid salt of amlodipine gentisate and a method of its preparation. More particularly, the present invention relates to a crystalline acid salt of amlodipine gentisate of the following formula 1 prepared by reacting amlodipine and gentisic acid, which is useful for the treatment of cardiovascular diseases and has the advantages of low toxicity, excellent stability, improved pharmaceutical efficacies and long-lasting concentration in blood.

Abstract: The present invention relates to a method for optical resolution of amlodipines by using isopropanol solvent and optically active O,O?-dibenzoyl tartaric acid as chiral reagent. More particularly, the present invention relates to a method comprising (a) obtaining (R)— or (S)-amlodipine dibenzoyl tartrate salt or solvate thereof by reacting (R,S)-amlodipines with optically active O,O?-dibenzoyl tartaric acid in isopropanol solvent, and (b) treating the (R)— or (S)-amlodipine salt with a base, thus obtaining optically active amlodipine.

Abstract: A network parameter automatic configuration apparatus and a method of a portable terminal are provided. The network parameter automatic configuration apparatus includes a memory, a configuration database, a smart card, a configuration searcher and a configuration processor. According to the present invention, without any addition user actions for network parameter configuration, the network parameters can be automatically configured and user convenience can be enhanced thereby.

Abstract: The present invention relates to novel quinazoline derivatives effective in lowering blood glucose level and body weight, and a medicine for treatment and/or prevention of diabetes and/or obesity, which comprises the compound as an active ingredient.